Savara, Inc. is a high-risk, high-reward biotech focused solely on Molbreevi for treating autoimmune pulmonary alveolar proteinosis (aPAP). SVRA plans to resubmit its BLA for Molbreevi in Q4 2025, ...

Autoimmune PAP is the most common form of PAP resulting in the buildup of surfactant in the air sacs of the lungs. There is no cure for this chronic lung condition, but there are treatment options to ...

89, passed away August 25, 2025. Arrangements provided by Harper-Morris Memorial Chapel. Services on Sep 02, 12:30pm at Holy Cross Episcopal Church. Barrancas National Cemetery.

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte–macrophage ...

Abstract: this study proposes an intelligent detection method for the compression quality inspection of tension clamps in transmission lines, addressing the issues of low efficiency and insufficient ...

A CPAP machine is a medical device often recommended to folks who have sleep apnea or other disruptive sleep conditions. Wearers place a mask over their nose and mouth to deliver a continuous stream ...

(RTTNews) - Savara Inc. (SVRA), a biopharmaceutical company, Thursday announced that it has introduced the aPAP ClearPath Dried Blood Spot Test in the U.S. This new test builds on its prior ...

-- The Simple, No-cost Test Can Detect Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Autoantibodies in the Blood with Only a Finger Prick -- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc.